TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02761915

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Study: NCT02196493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 250mg azithromycin three times per week for 12 weeks
Study: NCT02761915

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Study: NCT00642928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day during 4 weeks
Study: NCT04467489

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.
Study: NCT00642928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF 2.649 5 mg
Description: one BF 2.649 capsule of 5 mg per day during 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF 2.649 10 mg
Description: One BF 2.649 capsule of 10 mg per day during 4 weeks
Study: NCT04467489

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.

Intervention type: OTHER
Intervention: observational
Description: There is no intervention for any group in this observational study.
Study: NCT03778775

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver sitffness measurement
Description: Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
Study: NCT02359851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03833947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lignocaine+bicarbonate
Description: ETT cuff was filled with mixture of 2% lignocaine with bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine+dexamethasone
Description: ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
Study: NCT00510874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pumarix™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
Study: NCT00642928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF 2.649 20 mg
Description: One BF 2.649 capsule of 20 mg per day during 4 weeks
Study: NCT00510874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pumarix™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pumarix™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pumarix™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pumarix™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix ™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix ™
Description: Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
Study: NCT03882775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: heparin with or without gpi during emergency PCI.
Study: NCT01689909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem-CR
Description: Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
Study: NCT03671473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
Study: NCT01739400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg tablet, once daily.
Description: Macitentan 10 mg tablet, once daily.
Study: NCT01049477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music group
Description: The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non music group
Description: Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
Study: NCT00642928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF 2.649 40 mg
Description: One BF 2.649 capsule of 40 mg per day during 4 weeks
Study: NCT04198818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH2710
Description: HH2710 is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the nanomolar range. The kinase selectivity assessment towards a panel of over 400 protein kinases showed that HH2710 barely inhibited other kinases at a concentration up to 1 μM, except the substantial inhibition against ERK1 (MAPK1), ERK2 (MAPK2) and the MAPK pathway upstream kinases MEK and RAF proteins.
Study: NCT01375959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo capsules orally twice a day for 6 weeks
Study: NCT01216995

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose A
Description: ADRC Dose A

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT04313387

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal tomography multivariate index derived from a support vector machine (CTMVI).
Description: MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal tomography multivariate index derived from a support vector machine (CTMVI).
Description: MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal tomography multivariate index derived from a support vector machine (CTMVI).
Description: MATHEMATICAL ALGORITHM: To build the equation extracted from SVM, 58 variables were used, some of them were extracted from the spreadsheet.. After the construction of these 58 feature vectors (FV), an SVM-derived index was created, which was called the corneal tomography multivariate index derived from a support vector machine (CTMVI). Considering that each patient represents a point on a cartesian plane with 58 dimensions (each coordinate representing one of the 58 FV), the role of SVM is to find the hyperplane that best separates the CG, KCG, and VAE-NT G subjects. A hyperplane is algebraically described by a linear equation; in this case, there are 59 coefficients, 58 of which are related to the FV and one independent coefficient representing the bias (which is a possible parallel dislocation of a given hyperplane).
Study: NCT03069794

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Use of stable force platform
Description: Use of stable force platform to appreciate the posture before and after spinal surgery
Study: NCT04010344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care Group
Description: Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~1. Reminders~2. Participant to CHO messaging~3. Home BP tracking~4. Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~5. CHO provider portal- The provider portal will include decision support tools.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
Study: NCT02263144

Intervention type: PROCEDURE
Intervention: virtual chromo-endoscopy using FICE Fujifilm Technology
Description: For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
Study: NCT04166331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
Study: NCT04012814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Bliss
Description: The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
Study: NCT02761915

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine

Intervention type: GENETIC
Group type: OTHER
Intervention: 1RG-CART
Study: NCT02761915

Intervention type: GENETIC
Group type: OTHER
Intervention: 1RG-CART
Study: NCT01616615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 150 mg/day oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule / day oral use
Study: NCT00320671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
Study: NCT00502710

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4876904
Description: Escalating doses, at a starting dose of 12.5mg po daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4876904
Description: Escalating doses, at a starting dose of 12.5mg po daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4876904
Description: Escalating doses, at a starting dose of 12.5mg po daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4876904
Description: Escalating doses, at a starting dose of 12.5mg po daily.
Study: NCT02612090

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment Beverage
Description: Strawberry

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment Beverage
Description: Placebo
Study: NCT01408537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JEVAC
Description: Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
Study: NCT03125642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
Study: NCT02761915

Intervention type: GENETIC
Group type: OTHER
Intervention: 1RG-CART

Intervention type: GENETIC
Group type: OTHER
Intervention: 1RG-CART

Intervention type: GENETIC
Group type: OTHER
Intervention: 1RG-CART
Study: NCT03181620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Dosing of Medication
Description: Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
Study: NCT04637360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet Tablets
Description: All study subjects were treated with a fixed dose of oral Cinacalcet (25 mg/day) from baseline to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: All hyperparathyroidism were treated as traditional therapy with oral calcitriol 0.25 mcg(dosage according to IPTH serum level) from baseline to 6 months.
Study: NCT02519153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
Study: NCT02042547

Intervention type: OTHER
Intervention: Tissue samples from the right atrium

Intervention type: OTHER
Intervention: Blood samples
Study: NCT00059332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
Study: NCT04002648

Intervention type: PROCEDURE
Intervention: Right minithoracotomy
Description: Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space

Intervention type: PROCEDURE
Intervention: Sternotomy
Description: Longitudinal resection of the sternum
Study: NCT00393250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
Study: NCT03612154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
Study: NCT05152745

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo OGGT
Description: After overnight fasting, blood glucose level was assessed through a capillary drop blood The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginger aqueous extract
Description: After overnight fasting, blood glucose level was assessed through a capillary drop blood The intervention group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water, followed by 100mL of ginger extract (0.2g). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups.~Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
Study: NCT01608984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.